Creative Commons source reading · Parkinson’s disease and related disorders
Alpha-synuclein in Parkinson's disease and other synucleinopathies: from overt neurodegeneration back to early synaptic dysfunction.
Paolo Calabresi; Alessandro Mechelli; Giuseppina Natale; Laura Volpicelli-Daley; Giulia Di Lazzaro; Veronica Ghiglieri
Originally published in Cell death & disease · 2023-03-01
From the article
Selected source text. JournalOS removes markup and shortens excerpts where indicated. The full article provides the complete context.
Abstract
Although the discovery of the critical role of α-synuclein (α-syn) in the pathogenesis of Parkinson's disease (PD) is now twenty-five years old, it still represents a milestone in PD research. Abnormal forms of α-syn trigger selective and progressive neuronal death through mitochondrial impairment, lysosomal dysfunction, and alteration of calcium homeostasis not only in PD but also in other α-syn-related neurodegenerative disorders such as dementia with Lewy bodies, multiple system atrophy, pure autonomic failure, and REM sleep behavior disorder. Furthermore, α-syn-dependent early synaptic and plastic alterations and the underlying mechanisms preceding overt neurodegeneration have attracted great interest. In particular, the presence of early inflammation in experimental models and PD patients, occurring before deposition and spreading of α-syn, suggests a mechanistic link between inflammation and synaptic dysfunction. The knowledge of these early mechanisms is of seminal importance to support the research on reliable biomarkers to precociously identify the disease and possible disease-modifying therapies targeting α-syn.
Conclusions
More than twenty years of investigation on the role of α-syn in PD and the development of potential strategies to target this molecule to cure the disease represent a long story. It might somehow recall to our mind the long journey that has represented the story of the discovery of the central role of DA in PD and the subsequent development of successful symptomatic DA-based therapies. It is also possible that targeting only α-syn might not be sufficient to modify the natural history of the disease, and other molecular culprits must be identified and targeted.
Editorial reading guide
- Was the evidence cross-sectional, longitudinal or experimental?
- How did the authors account for age, disease stage and differences among participants?
